HRCM
BCRX icon

Hood River Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Hood River Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,620,261
Closed -$27.5M – 178
2025
Q3 		$27.5M Buy
3,620,261
+2,376,327
+191% +$19.8M 0.32% 89
2025
Q2 		$11.1M Buy
+1,243,934
New +$11.6M 0.16% 114

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Hood River Capital Management's BCRX Position: Q4 2025 in Review

Hood River Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 3,620,261 shares — an estimated $27.5M sold.

Hood River Capital Management first reported a position in BCRX in Q2 2025 and held it in 2 quarters. The position peaked at $27.5M in Q3 2025. 272 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Hood River Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Hood River Capital Management sold 3,620,261 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $27.5M.
  • Hood River Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Hood River Capital Management's BioCryst Pharmaceuticals position peaked at $27.5M in Q3 2025.
  • 272 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Hood River Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.